A Phase 1 interventional study of Drug Cocktail and Abemaciclib in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 43rd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2016, is one of 43 in phase 1, and was the 48th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 24 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 16 · Phase 3 10 · Phase 4 1
First in 2002; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 77 across the 66 interventional studies, 1,610 across the 1 observational. Of the 54 that completed or were terminated, 37 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Neoplasm Metastasis by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is known as a "drug interaction study" and is being done to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each participant will complete screening and four study periods in a fixed sequence, with the option to continue to receive abemaciclib in a safety extension phase. All participants will complete a safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.
Drug: Drug Cocktail
200 mg Abemaciclib administered orally every 12 hours (Q12H) on Days 1 - 12 in Period 2 with a single dose of drug cocktail: 100 mgcaffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 8 in Period 2.
Drug: Drug Cocktail · Drug: Abemaciclib
200 mg Abemaciclib administered orally Q12H on Days 13 to 28 in Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
Drug: Abemaciclib
200 mg Abemaciclib administered orally Q12H on Days 1 to 28 in Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
Drug: Abemaciclib
200 mg Abemaciclib administered orally Q12H on Days 1 to 28 onwards in extension period. Participants may continue to receive abemaciclib until discontinuation criteria are met.
Drug: Abemaciclib
Drug pages: Caffeine · Warfarin · Dextromethorphan · Midazolam · Omeprazole · Vitamin K 1
Administered orally
Also known as: Caffeine + Warfarin + Dextromethorphan + Midazolam
Administered orally
Also known as: LY2835219
Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine
Maximum concentration of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours (hr) Postdose
Pharmacokinetics: Maximum Concentration (Cmax) S-Warfarin
Maximum concentration of S-warfarin after single dose of drug cocktail on Day 1 in Period 1and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5 1, 2, 3, 4, 6, 8, 12, 48, 72, 96 hr Postdose
Pharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan
Maximum concentration of dextromethorphan after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72 hr postdose
Pharmacokinetics: Maximum Concentration (Cmax) of Midazolam
Maximum concentration of midazolam after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine
PK: AUC zero to infinity of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hr Postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin
AUC (zero to infinity) of S-warfarin after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hr Postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan
PK: AUC (zero to infinity) of dextromethorphan after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: 1, 2, 4, 6, 8, 10, 24, 48, 72 hr Postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam
PK: AUC (zero to infinity) of midazolam after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 1
Mean change from predose in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose drug cocktail in Period 1.
Time frame: Day 8: Baseline, 24 h postdose
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 1
Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 1.
Time frame: Day 8: Baseline, 24 h postdose
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2
Mean change from baseline in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose of abemaciclib in Period 2, Day 1.
Time frame: Day 1: Baseline, 24 h postdose
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2
Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 2, Day 1.
Time frame: Day 1: Baseline, 24 h postdose
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2
Mean change from baseline in systolic and diastolic blood pressure (BP) at 24 h postdose following 200 mg abemaciclib and drug cocktail.
Time frame: Day 8: Baseline, 24 h postdose
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2
Mean change from baseline in pulse rate at 24 h postdose following 200 mg abemaciclib and drug cocktail.
Time frame: Day 8: Baseline, 24 h postdose
Abemaciclib dose adjustments were allowed due to drug-related toxicity. Before the start of each cycle, drug-related toxicities must have resolved to either baseline or at least Grade 2. Participants not recovered from toxicities within 14 days were discontinued from the study. For Period 2, if abemaciclib dose adjustments occurred, dosing with the drug cocktail was permitted to be delayed to allow for adequate exposure.
| Milestone | Drug Cocktail - Period 1 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Period 3 | 200 mg Abemaciclib Period - 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| Started | 44 | 0 | 0 | 0 | 0 |
| Received one dose of drug cocktail | 44 | 0 | 0 | 0 | 0 |
| Completed | 44 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Drug Cocktail - Period 1 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Period 3 | 200 mg Abemaciclib Period - 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| Started | 0 | 44 | 0 | 0 | 0 |
| Received at least one dose of study drug | 0 | 42 | 0 | 0 | 0 |
| Completed | 0 | 37 | 0 | 0 | 0 |
| Not completed | 0 | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 |
| Milestone | Drug Cocktail - Period 1 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Period 3 | 200 mg Abemaciclib Period - 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 37 | 0 | 0 |
| Received at least one dose of study drug | 0 | 0 | 36 | 0 | 0 |
| Completed | 0 | 0 | 29 | 0 | 0 |
| Not completed | 0 | 0 | 8 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 7 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Milestone | Drug Cocktail - Period 1 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Period 3 | 200 mg Abemaciclib Period - 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 29 | 0 |
| Completed | 0 | 0 | 0 | 21 | 0 |
| Not completed | 0 | 0 | 0 | 8 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 7 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Milestone | Drug Cocktail - Period 1 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Period 3 | 200 mg Abemaciclib Period - 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 18 |
| Received at least one dose of study drug | 0 | 0 | 0 | 0 | 18 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 18 |
| Withdrew: Met discontinuation criteria | 0 | 0 | 0 | 0 | 18 |
Maximum concentration of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| nanograms per milliliter (ng/mL) | 100 mg Caffeine | Abemaciclib + 100 mg Caffeine |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine | 2890 ± 29 | 2950 ± 33 |
Maximum concentration of S-warfarin after single dose of drug cocktail on Day 1 in Period 1and in combination with Abemaciclib on Day 8 in Period 2.
| ng/mL | 10 mg Warfarin | 200 mg Abemaciclib + 10 mg Warfarin |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) S-Warfarin | 561 ± 35 | 526 ± 35 |
Maximum concentration of dextromethorphan after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| ng/mL | 30 mg Dextromethorphan | 200 Abemaciclib + 30 mg Dextromethorphan |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan | 3.18 ± 182 | 3.30 ± 164 |
Maximum concentration of midazolam after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| ng/mL | 0.2 mg Midazolam (Drug Cocktail) | 200 mg Abemaciclib + 0.2 mg Midazolam |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Midazolam | 2.12 ± 54 | 1.75 ± 48 |
PK: AUC zero to infinity of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| nanograms*hour per milliliter (ng*h/mL) | 100 mg Caffeine | 200 mg Abemaciclib + 100 mg Caffeine |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine | 32500 ± 72 | 47100 ± 89 |
AUC (zero to infinity) of S-warfarin after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| ng*h/mL | 10 mg Warfarin | 200 mg Abemaciclib + 10 mg Warfarin |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin | 21400 ± 43 | 20600 ± 40 |
PK: AUC (zero to infinity) of dextromethorphan after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| ng*h/mL | 30 mg Dextromethorphan | 200 mg Abemaciclib + 30 mg Dextromethorphan |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan | 32.6 ± 316 | 32.1 ± 238 |
PK: AUC (zero to infinity) of midazolam after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.
| ng*h/mL | 0.2 mg Midazolam | 200 mg Abemaciclib + 0.2 mg Midazolam |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam | 7.34 ± 74 | 6.03 ± 63 |
Mean change from predose in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose drug cocktail in Period 1.
| millimeter of mercury (mmHg) | Drug Cocktail Period 1 |
|---|---|
| Systolic BP | -2.5 ± 13.9 |
| Diastolic BP | -0.7 ± 10.1 |
Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 1.
| Beats per minute (bpm) | Drug Cocktail Period 1 |
|---|---|
| Mean Change From Baseline at 24 Hours in Pulse Rate in Period 1 | -1.3 ± 11.1 |
Mean change from baseline in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose of abemaciclib in Period 2, Day 1.
| mmHg | 200 mg Abemaciclib |
|---|---|
| Systolic BP | -7.8 ± 15.2 |
| Diastolic BP | -1.8 ± 10.4 |
Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 2, Day 1.
| bpm | 200 mg Abemaciclib |
|---|---|
| Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2 | -0.2 ± 12.5 |
Mean change from baseline in systolic and diastolic blood pressure (BP) at 24 h postdose following 200 mg abemaciclib and drug cocktail.
| mmHg | 200 mg Abemaciclib + Drug Cocktail |
|---|---|
| Systolic BP | -11.6 ± 16.8 |
| Diastolic BP | -6.1 ± 10.5 |
Mean change from baseline in pulse rate at 24 h postdose following 200 mg abemaciclib and drug cocktail.
| bpm | 200 mg Abemaciclib + Drug Cocktail |
|---|---|
| Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2 | 4.1 ± 14.9 |
Collected over Baseline up to 46 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Drug Cocktail - Period 1 | 1/44 (2.3%) | 1/44 (2.3%) | 22/44 (50%) |
| 200 mg Abemaciclib - Period 2 | 0/42 (0%) | 3/42 (7.1%) | 33/42 (78.6%) |
| 200 mg Abemaciclib + Drug Cocktail - Period 2 | 0/35 (0%) | 2/35 (5.7%) | 26/35 (74.3%) |
| 200 mg Abemaciclib - Periods 3 and 4 | 0/28 (0%) | 6/28 (21.4%) | 25/28 (89.3%) |
| Abemaciclib Safety Extension Period | 0/18 (0%) | 2/18 (11.1%) | 16/18 (88.9%) |
| Event | Drug Cocktail - Period 1 | 200 mg Abemaciclib - Period 2 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Periods 3 and 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| ColitisGastrointestinal disorders | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| OesophagitisGastrointestinal disorders | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| PancreatitisGastrointestinal disorders | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| Clostridium difficile colitisInfections and infestations | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| DiverticulitisInfections and infestations | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/44 | 0/42 | 0/35 | 0/28 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 0/44 | 0/42 | 1/35 | 1/28 | 0/18 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/44 | 0/42 | 0/35 | 1/28 | 0/18 |
| SepsisInfections and infestations | 0/44 | 0/42 | 0/35 | 1/28 | 0/18 |
| Urinary tract infectionInfections and infestations | 0/44 | 0/42 | 0/35 | 1/28 | 0/18 |
| Event | Drug Cocktail - Period 1 | 200 mg Abemaciclib - Period 2 | 200 mg Abemaciclib + Drug Cocktail - Period 2 | 200 mg Abemaciclib - Periods 3 and 4 | Abemaciclib Safety Extension Period |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/44 | 18/42 | 11/35 | 12/28 | 2/18 |
| Decreased appetiteMetabolism and nutrition disorders | 1/44 | 3/42 | 4/35 | 6/28 | 5/18 |
| NauseaGastrointestinal disorders | 5/44 | 8/42 | 6/35 | 7/28 | 4/18 |
| VomitingGastrointestinal disorders | 2/44 | 8/42 | 5/35 | 7/28 | 4/18 |
| AnaemiaBlood and lymphatic system disorders | 0/44 | 1/42 | 2/35 | 6/28 | 2/18 |
| FatigueGeneral disorders | 1/44 | 6/42 | 6/35 | 5/28 | 3/18 |
| HypokalaemiaMetabolism and nutrition disorders | 0/44 | 5/42 | 0/35 | 5/28 | 3/18 |
| Abdominal painGastrointestinal disorders | 2/44 | 6/42 | 2/35 | 2/28 | 3/18 |
| ConstipationGastrointestinal disorders | 2/44 | 3/42 | 4/35 | 1/28 | 3/18 |
| Urinary tract infectionInfections and infestations | 2/44 | 1/42 | 0/35 | 0/28 | 3/18 |
All participants who received at least one dose of drug cocktail.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 60.1 ± 11.0 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 20 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 41 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| United States | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2016 to primary completion in Feb 2018, 22 months.
Results were first posted in Oct 2022, 4 years 8 months after primary completion.
Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 22 months is below that.
Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Caffeine · Warfarin · Dextromethorphan · Midazolam · Omeprazole · Vitamin K 1 · Abemaciclib